CLS THERAPEUTICS LIMITED Patent applications |
Patent application number | Title | Published |
20160130570 | METHOD FOR TREATING ONCOLOGICAL DISEASES - A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days. | 05-12-2016 |
20150110769 | METHOD FOR RETARDING UNHEALTHY MANIFESTATIONS BROUGHT BY AGEING OF HUMAN BEINGS - The present invention provides a method for retarding unhealthy manifestations brought by ageing of human beings (in particular, but not limited to the reduction of sexual activity and fertility, climax, changes in glucose tolerance, reduction of cognitive and mnestic functions, reduction of stress resistance, development of organ and tissue sclerosis). According to the invention this task is solved by administration into the blood circulation of an agent which inactivates extracellular blood plasma DNA e.g. a DNase enzyme. | 04-23-2015 |
20150010523 | METHOD FOR TREATING SYSTEMIC DNA MUTATION DISEASE - The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient. | 01-08-2015 |
20140193389 | METHOD FOR TREATING ONCOLOGICAL DISEASES - A method to treat cancer and other malignant diseases, said method comprising parenterally administering an agent which destroys blood extracellular DNA into the systemic circulation of a cancer patient to slow down cancer growth. The agent is embodied in the form of a DNase enzyme and, more particularly, as a DNase I enzyme. Doses from 50,000-250,000,000 Kunitz units/day are administered for 5-360 days. | 07-10-2014 |
20130216516 | METHOD FOR TREATING DELAYED-TYPE HYPERSENSITIVITY - The invention is directed to treatment of delayed-type hypersensitivity reactions associated with changes of qualitative and/or quantitative composition of blood extracellular DNA and treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient. | 08-22-2013 |
20130183284 | Method for Treating Systemic Bacterial, Fungal and Protozoan Infection - The invention is directed to a treatment of systemic bacterial, fungal and protozoan infections. The inventive method comprises introducing a DNase enzyme into a circulating blood system of a patient diagnosed with systemic infection caused by bacteria, fungi or protozoa, wherein said DNase enzyme destroys extracellular DNA in said blood of said patient, said DNase enzyme being administered in doses and regimens which are sufficient to decrease the average molecular weight of circulating extracellular blood DNA in the blood of said patient. | 07-18-2013 |
20130183283 | Method for Treating Systemic DNA Mutation Disease - The invention is directed to treatment of systemic DNA mutation diseases accompanied with development of somatic mosaicism and elevation of blood extracellular DNA. The inventive method comprises introducing a DNASE enzyme into the systemic blood circulation of a patient in doses and regimens which are sufficient to decrease average molecular weight of circulating extracellular blood DNA in the blood of said patient. | 07-18-2013 |